{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:49:25Z","timestamp":1786121365337,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study seeks to explore the impact of lean and non-lean phenotypes of metabolic dysfunction-associated steatotic liver disease (MASLD) on the prevalence of advanced cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome stage in individuals with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on a BMI cutoff of 23 kg\/m\u00b2, 705 hospitalized patients with T2DM and MASLD were split into lean and non-lean categories. Data on clinical characteristics, fat distribution, liver and kidney function, and metabolic markers were collected. The relationship between MASLD phenotypes and concurrent CKM staging severity was evaluated using multivariate logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In patients with T2DM and MASLD, 26.7% had lean MASLD. When accounting for age, gender, and diabetes duration, the non-lean MASLD group had higher rates of cardiovascular events (21.3% compared to 10.1%), cerebrovascular events (18.0% compared to 12.2%), and CKM stage 4 (33.5% compared to 18.6%) than the lean group (all P &amp;lt; 0.05). There was no notable difference in the prevalence of CKM stage 3 (61.9% vs. 56.9%, P = 0.148). Binary logistic regression analysis indicated that non-lean MASLD was independently associated with a higher prevalence of advanced stage of CKM, in comparison to lean MASLD (OR = 2.674, P &amp;lt; 0.001). Higher levels of visceral fat area, insulin resistance, and C-peptide were observed in the non-lean group (all P &amp;lt; 0.05), with liver fibrosis indices remaining similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with T2DM and MASLD, non-lean MASLD exhibits an independent positive correlation with severe CKM syndrome when compared to lean MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1910398","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:22:27Z","timestamp":1786076547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-lean versus lean MASLD: associations with advanced cardiovascular-kidney-metabolic syndrome in adults with type 2 diabetes mellitus, a cross-sectional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Jun-Wei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Endocrinology Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, The Key Laboratory of Endocrine and Metabolic Diseases of Shanxi Province","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Inner Mongolia Autonomous Region People\u2019s Hospital","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, The Key Laboratory of Endocrine and Metabolic Diseases of Shanxi Province","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, The Key Laboratory of Endocrine and Metabolic Diseases of Shanxi Province","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Nan","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, The Key Laboratory of Endocrine and Metabolic Diseases of Shanxi Province","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1168499","article-title":"Analysis of risk factors related to nonalcoholic fatty liver disease: a retrospective study based on 31,718 adult Chinese individuals","volume":"10","author":"Wang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","volume":"19","author":"Eslam","year":"2025","journal-title":"Hepatol Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2023.44.9.20230021","article-title":"Epidemiology of lean\/non-obese nonalcoholic fatty liver disease in China: A systematic review and meta-analysis","volume":"44","author":"Zhang","year":"2023","journal-title":"Saudi Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8429847","article-title":"Metabolic (Dysfunction)-associated fatty liver disease in chinese patients with type 2 diabetes from a subcenter of the national metabolic management center","volume":"2022","author":"Guan","year":"2022","journal-title":"J Diabetes Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10143-4","article-title":"The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040","volume":"15","author":"Ito","year":"2021","journal-title":"Hepatol Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042096","article-title":"Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China","volume":"19","author":"Yuan","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2022.01.006","article-title":"Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study","volume":"21","author":"Zeng","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15259","article-title":"Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea","volume":"42","author":"Kim","year":"2022","journal-title":"Liver Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10801-x","article-title":"Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis","volume":"19","author":"Cheah","year":"2025","journal-title":"Hepatol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01045-z","article-title":"Metabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment","volume":"22","author":"Byrne","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and Malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: Proposing an expanded framework","volume":"15","author":"Theodorakis","year":"2025","journal-title":"Biomolecules"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60968","article-title":"Mortality, hepatic decompensation, and cardiovascular- and renal-related outcomes in lean versus non-lean patients hospitalized with metabolic dysfunction-associated steatohepatitis (MASH)","volume":"16","author":"Ezeani","year":"2024","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10407-7","article-title":"Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","article-title":"Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity","volume":"15","author":"Fracanzani","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18459","article-title":"Non-obese non-alcoholic fatty liver disease and the risk of chronic kidney disease: a systematic review and meta-analysis","volume":"12","author":"You","year":"2024","journal-title":"PeerJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)","volume":"78","author":"Nabi","year":"2023","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.09.012","article-title":"Comparison of risk factors between lean and nonlean metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes: A multicenter study","volume":"30","author":"Sun","year":"2024","journal-title":"Endocr Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12933-022-01648-9","article-title":"Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12933-016-0360-2","article-title":"The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes","volume":"15","author":"Li","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad047","article-title":"Transitions in metabolic health status and obesity over time and risk of diabetes: The Dongfeng-Tongji cohort study","volume":"108","author":"Wei","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0222","article-title":"Serum retinol-binding protein levels are associated with nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus: A real-world study","volume":"46","author":"Zhang","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10977","DOI":"10.1038\/s41598-022-14701-0","article-title":"Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S462003","article-title":"Cardiometabolic and metabolic profiles of lean\/normal, overweight and obese patients with nonalcoholic fatty liver disease","volume":"17","author":"Wang","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102569","article-title":"Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis","volume":"49","author":"Nso","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336127","article-title":"Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts","volume":"75","author":"Huo","year":"2026","journal-title":"Gut"},{"key":"B32","doi-asserted-by":"publisher","first-page":"104753","DOI":"10.1016\/j.numecd.2026.104753","article-title":"Polyvascular subclinical atherosclerosis differs across metabolic dysfunction-associated fatty liver disease subtypes: a community-based cross-sectional study","author":"Chen","year":"2026","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10517-w","article-title":"Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease","volume":"17","author":"Kang","year":"2023","journal-title":"Hepatol Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1515\/dx-2023-0159","article-title":"Interleukin-6, tumor necrosis factor-\u03b1, and high-sensitivity C-reactive protein for optimal immunometabolic profiling of the lifestyle-related cardiorenal risk","volume":"11","author":"Marchiori","year":"2024","journal-title":"Diagnosis (Berl)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000535772","article-title":"Mechanistic links between central obesity and cardiorenal metabolic diseases","volume":"14","author":"Al-Chalabi","year":"2024","journal-title":"Cardiorenal Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-026-01066-0","article-title":"Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects","volume":"22","author":"Zaitoon","year":"2026","journal-title":"Nat Rev Nephrol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94134","article-title":"Cardio-renal metabolic syndrome: An integrated approach to prevention and management","volume":"17","author":"Singh","year":"2025","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000539804","article-title":"Perspectives in managing kidney disease and atherosclerotic cardiovascular disease","volume":"14","author":"Namvar","year":"2024","journal-title":"Cardiorenal Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/20420188241274310","article-title":"Analyzing and evaluating the prevalence and metabolic profile of lean NAFLD compared to obese NAFLD: a systemic review and meta-analysis","volume":"15","author":"Fatima","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030324","article-title":"Linking cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD): The role of cardiometabolic drugs in MASLD treatment","volume":"15","author":"Zisis","year":"2025","journal-title":"Biomolecules"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1910398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:22:28Z","timestamp":1786076548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1910398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":40,"alternative-id":["10.3389\/fendo.2026.1910398"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1910398","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"1910398"}}